OMV Q4 2025 Conference Call - Q&A Transcript. OMV published its results for Q4 2025 on February 4, 2026 ... OMV Group ... OMV Group ... In the Pelican field, OMV Petrom wanted to drill four wells ... OMV Petrom ...
OMV Q4 2025 Conference Call - Q&A Transcript. OMV published its results for Q4 2025 on February 4, 2026 ... OMV Group ... OMV Group ... In the Pelican field, OMV Petrom wanted to drill four wells ... OMV Petrom ...
OMV Petrom Q4 2025 Conference Call - Q&A Transcript. OMV Petrom published its results for January - December and Q4 2025 on February 4, 2026 ... OMV's guidance, which expects higher opex/boe this year.
DX-104 is an engineered MenB vaccine candidate developed using Delonix's proprietary OMVPlus® platform. The platform leverages precisely engineered outer membrane vesicles (OMVs) with intrinsic adjuvant properties to optimize immunogenicity.
OMV Petrom delivers resilient results with record investments of 7.8 billion lei and progresses on key projects amid market volatility. Christina Verchere, CEO OMV Petrom ... ~20.5 mn euro OMV Petrom Foundation ... OMV Petrom.
OMV today announced its results for the 2025 financial year, 2 with a clean CCS Operating Result of EUR 4.6 billion and clean CCS net income attributable to stockholders of EUR 1.9 billion ... You can find the OMV GroupReport 2025 here.